

# Ric M Procyshyn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4477631/publications.pdf>

Version: 2024-02-01

137  
papers

3,465  
citations

212478

28  
h-index

214428

50  
g-index

142  
all docs

142  
docs citations

142  
times ranked

3783  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of long-acting injectable versus oral antipsychotic drugs in early psychosis: A systematic review and meta-analysis. <i>Microbial Biotechnology</i> , 2022, 16, 589-599.	0.9	27
2	Pain, opioid use, depressive symptoms, and mortality in adults living in precarious housing or homelessness: a longitudinal prospective study. <i>Pain</i> , 2022, 163, 2213-2223.	2.0	4
3	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. <i>Pharmacopsychiatry</i> , 2022, 55, 73-86.	1.7	107
4	Antipsychotic Drug-Induced Increases in Peripheral Catecholamines are Associated With Glucose Intolerance. <i>Frontiers in Pharmacology</i> , 2022, 13, 765905.	1.6	3
5	Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review. <i>PLoS ONE</i> , 2022, 17, e0267808.	1.1	15
6	Differential effects of cannabis exposure during early versus later adolescence on the expression of psychosis in homeless and precariously housed adults. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 106, 110084.	2.5	7
7	Dynamic networks of psychotic symptoms in adults living in precarious housing or homelessness. <i>Psychological Medicine</i> , 2021, , 1-11.	2.7	3
8	A Focused Review of the Metabolic Side-Effects of Clozapine. <i>Frontiers in Endocrinology</i> , 2021, 12, 609240.	1.5	32
9	Relationship between clozapine dose and severity of obsessive-compulsive symptoms. <i>Medical Hypotheses</i> , 2021, 148, 110506.	0.8	1
10	Efficacy and tolerability of aripiprazole versus D2 antagonists in the early course of schizophrenia: a systematic review and meta-analysis. <i>NPJ Schizophrenia</i> , 2021, 7, 29.	2.0	13
11	Component Processes of Decision Making in a Community Sample of Precariously Housed Persons: Associations With Learning and Memory, and Health-Risk Behaviors. <i>Frontiers in Psychology</i> , 2021, 12, 571423.	1.1	0
12	A ganglionic blocker and adrenoceptor ligands modify clozapine-induced insulin resistance. <i>Psychoneuroendocrinology</i> , 2021, 129, 105257.	1.3	3
13	Exercise and Worsening of Extrapyrimal Symptoms during Treatment with Long-Acting Injectable Antipsychotics. <i>Pharmacy (Basel, Switzerland)</i> , 2021, 9, 123.	0.6	3
14	Characterization of Bodily Pain and Use of Both Prescription and Non-Prescription Opioids in Tenants of Precarious Housing. <i>Substance Use and Misuse</i> , 2021, 56, 1951-1961.	0.7	5
15	Population pharmacokinetics and dosing of long-acting injectable antipsychotics. <i>Journal of Psychiatry and Neuroscience</i> , 2021, 46, E516-E517.	1.4	0
16	A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models. <i>PLoS ONE</i> , 2021, 16, e0246211.	1.1	6
17	Decreased medial entorhinal cortical thickness in olanzapine exposed female rats is not ameliorated by exercise. <i>Pharmacology Biochemistry and Behavior</i> , 2020, 188, 172834.	1.3	0
18	Cognitive decline and mortality in a community-based sample of homeless and precariously housed adults: 9-year prospective study. <i>BJPsych Open</i> , 2020, 6, e21.	0.3	22

#	ARTICLE	IF	CITATIONS
19	Differential Effects of Acute Treatment With Antipsychotic Drugs on Peripheral Catecholamines. <i>Frontiers in Psychiatry</i> , 2020, 11, 617428.	1.3	18
20	Associations of substance use, psychosis, and mortality among people living in precarious housing or homelessness: A longitudinal, community-based study in Vancouver, Canada. <i>PLoS Medicine</i> , 2020, 17, e1003172.	3.9	32
21	Clozapine-Associated Obsessive-Compulsive Symptoms and Their Management: A Systematic Review and Analysis of 107 Reported Cases. <i>Psychotherapy and Psychosomatics</i> , 2020, 89, 151-160.	4.0	19
22	How many clients with refractory psychosis are eligible for both cognitive-behaviour therapy and clozapine? A chart-review study. <i>Cogent Psychology</i> , 2019, 6, 1611208.	0.6	0
23	Cognitive Impairment in Marginally Housed Youth: Prevalence and Risk Factors. <i>Frontiers in Public Health</i> , 2019, 7, 270.	1.3	12
24	Cognitive profiles and associated structural brain networks in a multimorbid sample of marginalized adults. <i>PLoS ONE</i> , 2019, 14, e0218201.	1.1	9
25	A comparison of regional brain volumes and white matter connectivity in subjects with stimulant induced psychosis versus schizophrenia. <i>Psychopharmacology</i> , 2019, 236, 3385-3399.	1.5	10
26	Diffusion tensor imaging of neurocognitive profiles in a community cohort living in marginal housing. <i>Brain and Behavior</i> , 2019, 9, e01233.	1.0	7
27	Clozapine-induced obsessive-compulsive symptoms: mechanisms and treatment. <i>Journal of Psychiatry and Neuroscience</i> , 2019, 44, 71-72.	1.4	19
28	Need for Bioequivalence Standards that Reflect the Clinical Importance of the Complex Pharmacokinetics of Paliperidone Palmitate Long-Acting Injectable Suspension. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2019, 22, 548-566.	0.9	4
29	Characterization of mental health in cannabis dispensary users, using structured clinical interviews and standardized assessment instruments. <i>BMC Psychiatry</i> , 2019, 19, 335.	1.1	13
30	Volumes of the Hippocampal Formation Differentiate Component Processes of Memory in a Community Sample of Homeless and Marginally Housed Persons. <i>Archives of Clinical Neuropsychology</i> , 2019, 34, 548-562.	0.3	9
31	Management of sexual adverse effects induced by atypical antipsychotic medication. <i>Journal of Psychiatry and Neuroscience</i> , 2019, 44, 287-288.	1.4	6
32	Association between Serum Lipids and Antipsychotic Response in Schizophrenia. <i>Current Neuropharmacology</i> , 2019, 17, 852-860.	1.4	26
33	Reduced cardiovascular fitness associated with exposure to clozapine in individuals with chronic schizophrenia. <i>Psychiatry Research</i> , 2018, 262, 28-33.	1.7	8
34	Exercise-induced hippocampal neurogenesis: 5-HT <sub>3</sub> receptor antagonism by antipsychotics as a potential limiting factor in Schizophrenia. <i>Molecular Psychiatry</i> , 2018, 23, 2252-2253.	4.1	5
35	Effects of physical activity on the symptoms of Tourette syndrome: A systematic review. <i>European Psychiatry</i> , 2018, 48, 13-19.	0.1	18
36	Statin add-on therapy for schizophrenia: Is the effect the same for clozapine?. <i>Psychiatry Research</i> , 2018, 263, 289-290.	1.7	3

#	ARTICLE	IF	CITATIONS
37	Risk of hair loss with different antidepressants. <i>International Clinical Psychopharmacology</i> , 2018, 33, 44-48.	0.9	1
38	Clozapine, elevated heart rate and QTc prolongation. <i>Journal of Psychiatry and Neuroscience</i> , 2018, 43, 71-72.	1.4	18
39	Antipsychotic prescribing patterns on admission to and at discharge from a tertiary care program for treatment-resistant psychosis. <i>PLoS ONE</i> , 2018, 13, e0199758.	1.1	8
40	A systematic review of the effects of CYP2D6 phenotypes on risperidone treatment in children and adolescents. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2018, 12, 37.	1.2	17
41	Clozapine-Induced Cardiovascular Side Effects and Autonomic Dysfunction: A Systematic Review. <i>Frontiers in Neuroscience</i> , 2018, 12, 203.	1.4	47
42	Clinical and functional characteristics of young adults living in single room occupancy housing: preliminary findings from a 10-year longitudinal study. <i>Canadian Journal of Public Health</i> , 2018, 109, 204-214.	1.1	22
43	Reversal of Dopamine Supersensitivity as a Mechanism of Action of Clozapine. <i>Psychotherapy and Psychosomatics</i> , 2018, 87, 306-307.	4.0	11
44	Antipsychotic-Associated Symptoms of Tourette Syndrome: A Systematic Review. <i>CNS Drugs</i> , 2018, 32, 917-938.	2.7	15
45	Association of Antidepressant Use With Drug-Related Extrapramidal Symptoms. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 349-356.	0.7	21
46	Housing First Improves Adherence to Antipsychotic Medication Among Formerly Homeless Adults With Schizophrenia: Results of a Randomized Controlled Trial. <i>Schizophrenia Bulletin</i> , 2017, 43, sbw136.	2.3	21
47	Characterization of white matter integrity deficits in cocaine-dependent individuals with substance-induced psychosis compared with non-psychotic cocaine users. <i>Addiction Biology</i> , 2017, 22, 873-881.	1.4	12
48	A comparison of psychotic symptoms in subjects with methamphetamine versus cocaine dependence. <i>Psychopharmacology</i> , 2017, 234, 1535-1547.	1.5	23
49	The Hotel Study—Clinical and Health Service Effectiveness in a Cohort of Homeless or Marginally Housed Persons. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 482-492.	0.9	38
50	Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 102-104.	0.7	46
51	Effects of Exercise on Serum Triglycerides and Symptoms of Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 273-274.	0.7	9
52	Structural brain markers are differentially associated with neurocognitive profiles in socially marginalized people with multimorbid illness. <i>Neuropsychology</i> , 2017, 31, 28-43.	1.0	13
53	Heart-rate response to alpha2-adrenergic receptor antagonism by antipsychotics. <i>Clinical Autonomic Research</i> , 2017, 27, 407-410.	1.4	5
54	Traumatic Brain Injury in a Community-Based Cohort of Homeless and Vulnerably Housed Individuals. <i>Journal of Neurotrauma</i> , 2017, 34, 3301-3310.	1.7	19

#	ARTICLE	IF	CITATIONS
55	Exercise-associated extrapyramidal symptoms during treatment with long-acting injectable antipsychotic medications: A case report. <i>Clinical Schizophrenia and Related Psychoses</i> , 2017, , .	1.4	2
56	Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review. <i>Current Neuropharmacology</i> , 2016, 15, 174-183.	1.4	63
57	A Tetra-Primer Amplification Refractory System Technique for the Cost-Effective and Novel Genotyping of Eight Single-Nucleotide Polymorphisms of the Catechol-O-Methyltransferase Gene. <i>Genetic Testing and Molecular Biomarkers</i> , 2016, 20, 465-470.	0.3	4
58	Risk of Extrapyramidal Adverse Events With Aripiprazole. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 472-474.	0.7	16
59	Proposing the Use of Partial AUC as an Adjunctive Measure in Establishing Bioequivalence Between Deltoid and Gluteal Administration of Long-Acting Injectable Antipsychotics. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2016, 41, 659-664.	0.6	8
60	Factors affecting severity of positive and negative symptoms of psychosis in a polysubstance using population with psychostimulant dependence. <i>Psychiatry Research</i> , 2016, 240, 336-342.	1.7	15
61	Subcortical grey matter alterations in cocaine dependent individuals with substance-induced psychosis compared to non-psychotic cocaine users. <i>Schizophrenia Research</i> , 2016, 176, 158-163.	1.1	10
62	Response to the Letter to the Editor on "Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle: Are They Therapeutically Equivalent?" <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 745-747.	0.7	0
63	Elevated clozapine plasma concentration secondary to a urinary tract infection: proposed mechanisms. <i>Journal of Psychiatry and Neuroscience</i> , 2016, 41, E67-E68.	1.4	12
64	Breakthrough symptoms after switching long-acting injectable paliperidone palmitate from the gluteal to the deltoid site of administration. <i>Journal of Psychiatry and Neuroscience</i> , 2016, 41, E56-E57.	1.4	7
65	Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 447-449.	0.7	25
66	Development of a cost-efficient novel method for rapid, concurrent genotyping of five common single nucleotide polymorphisms of the brain derived neurotrophic factor (BDNF) gene by tetra-primer amplification refractory mutation system. <i>International Journal of Methods in Psychiatric Research</i> , 2015, 24, 235-244.	1.1	7
67	Dimenhydrinate Use Disorder With Chronic Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 105-107.	0.7	3
68	White matter deficits assessed by diffusion tensor imaging and cognitive dysfunction in psychostimulant users with comorbid human immunodeficiency virus infection. <i>BMC Research Notes</i> , 2015, 8, 515.	0.6	26
69	Cognition and Plasma Ratio of Clozapine to <i>N</i> -desmethylclozapine in Patients With Clozapine-Resistant Schizophrenia. <i>American Journal of Psychiatry</i> , 2015, 172, 1259-1259.	4.0	11
70	Mortality from treatable illnesses in marginally housed adults: a prospective cohort study. <i>BMJ Open</i> , 2015, 5, e008876.	0.8	34
71	The Pharmacokinetics of Second-Generation Long-Acting Injectable Antipsychotics: Limitations of Monograph Values. <i>CNS Drugs</i> , 2015, 29, 975-983.	2.7	14
72	Therapeutic Drug Levels of Second Generation Antipsychotics in Youth: A Systematic Review. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 234-245.	0.7	24

#	ARTICLE	IF	CITATIONS
73	Response trajectories to clozapine in a secondary analysis of pivotal trials support using treatment response to subtype schizophrenia. <i>Canadian Journal of Psychiatry</i> , 2015, 60, S19-25.	0.9	11
74	An Evaluation of the Effects of the Novel Antipsychotic Drug Lurasidone on Glucose Tolerance and Insulin Resistance: A Comparison with Olanzapine. <i>PLoS ONE</i> , 2014, 9, e107116.	1.1	18
75	Neurocognitive profiles of marginally housed persons with comorbid substance dependence, viral infection, and psychiatric illness. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2014, 36, 1009-1022.	0.8	18
76	Managing ADHD and disruptive behaviour disorders with combination psychostimulant and antipsychotic treatment. <i>Journal of Psychiatry and Neuroscience</i> , 2014, 39, E32-E33.	1.4	3
77	Prevalence and Patterns of Antipsychotic Use in Youth at the Time of Admission and Discharge From an Inpatient Psychiatric Facility. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 17-22.	0.7	18
78	Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension. <i>International Clinical Psychopharmacology</i> , 2014, 29, 125-137.	0.9	41
79	Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 48, 170-176.	2.5	22
80	Clozapine administered once versus twice daily: Does it make a difference?. <i>Medical Hypotheses</i> , 2014, 82, 225-228.	0.8	17
81	Symptom changes in five dimensions of the Positive and Negative Syndrome Scale in refractory psychosis. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2014, 264, 673-682.	1.8	21
82	Cardiovascular effects of acute treatment with the antipsychotic drug olanzapine in rats. <i>Vascular Pharmacology</i> , 2014, 62, 143-149.	1.0	11
83	Antipsychotic and Psychostimulant Drug Combination Therapy in Attention Deficit/Hyperactivity and Disruptive Behavior Disorders: A Systematic Review of Efficacy and Tolerability. <i>Current Psychiatry Reports</i> , 2013, 15, 355.	2.1	44
84	Management of Medication-Related Cardiometabolic Risk in Patients with Severe Mental Illness. <i>Current Cardiovascular Risk Reports</i> , 2013, 7, 283-287.	0.8	11
85	A retrospective study of antipsychotic drug switching in a pediatric population. <i>BMC Psychiatry</i> , 2013, 13, 248.	1.1	7
86	Methamphetamine use: A comprehensive review of molecular, preclinical and clinical findings. <i>Drug and Alcohol Dependence</i> , 2013, 129, 167-179.	1.6	336
87	Metabolic Side-Effects of the Novel Second-Generation Antipsychotic Drugs Asenapine and loperidone: A Comparison with Olanzapine. <i>PLoS ONE</i> , 2013, 8, e53459.	1.1	36
88	The Hotel Study: Multimorbidity in a Community Sample Living in Marginal Housing. <i>American Journal of Psychiatry</i> , 2013, 170, 1413-1422.	4.0	82
89	Antipsychotic polypharmacy increases metabolic dysregulation in female rats.. <i>Experimental and Clinical Psychopharmacology</i> , 2013, 21, 164-171.	1.3	18
90	Personalized Risk Assessment of Drug-Related Harm Is Associated with Health Outcomes. <i>PLoS ONE</i> , 2013, 8, e79754.	1.1	10

#	ARTICLE	IF	CITATIONS
91	Adverse events associated with switching antipsychotics. <i>Journal of Psychiatry and Neuroscience</i> , 2012, 37, E1-E2.	1.4	8
92	Antipsychotic Medications: Linking Receptor Antagonism to Neuropsychological Functioning in First Episode Psychosis. <i>Journal of the International Neuropsychological Society</i> , 2012, 18, 717-727.	1.2	16
93	Cardiovascular side-effects of antipsychotic drugs: The role of the autonomic nervous system. , 2012, 135, 113-122.		125
94	Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. <i>Journal of Psychiatry and Neuroscience</i> , 2012, 37, 407-415.	1.4	52
95	Excessive Antipsychotic Dosing in a Canadian Outpatient Population. <i>Psychiatric Services</i> , 2011, 62, 682-683.	1.1	4
96	Withdrawal. <i>NeuroMethods</i> , 2011, , 431-459.	0.2	0
97	Differential Effects of Alcohol Intoxication on S100B Levels Following Traumatic Brain Injury. <i>Journal of Trauma</i> , 2010, 68, 1065-1071.	2.3	8
98	A Comparison of Antipsychotic Drug-Defined Daily Doses Versus Chlorpromazine Equivalent Doses in Patients With or Without Extrapyramidal Motor Symptoms. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 741-743.	0.7	11
99	Gender-specific profiles of tobacco use among non-institutionalized people with serious mental illness. <i>BMC Psychiatry</i> , 2010, 10, 101.	1.1	36
100	Long-acting injectable risperidone in treatment refractory patients: A 14-week open-label pilot study. <i>Schizophrenia Research</i> , 2010, 123, 273-275.	1.1	5
101	Smoking cessation interventions among individuals in methadone maintenance: A brief review. <i>Journal of Substance Abuse Treatment</i> , 2010, 38, 191-199.	1.5	41
102	A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 945-954.	2.5	65
103	Preclinical models of antipsychotic drug-induced metabolic side effects. <i>Trends in Pharmacological Sciences</i> , 2010, 31, 484-497.	4.0	97
104	Effect of hypertriglyceridemia on the pharmacokinetics and blood-brain barrier penetration of clozapine and nortriptyline following administration to rats. <i>European Neuropsychopharmacology</i> , 2010, 20, 545-552.	0.3	9
105	Medication Errors in Psychiatry. <i>CNS Drugs</i> , 2010, 24, 595-609.	2.7	42
106	Persistent Antipsychotic Polypharmacy and Excessive Dosing in the Community Psychiatric Treatment Setting. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 566-573.	1.1	104
107	Community mental healthcare providers' attitudes and practices related to smoking cessation interventions for people living with severe mental illness. <i>Patient Education and Counseling</i> , 2009, 77, 289-295.	1.0	55
108	Predictors of starting to smoke cigarettes in patients with first episode psychosis. <i>Schizophrenia Research</i> , 2009, 108, 258-264.	1.1	23

#	ARTICLE	IF	CITATIONS
109	Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia. <i>Current Medical Research and Opinion</i> , 2009, 25, 2121-2132.	0.9	16
110	Do serum lipids predict response to clozapine treatment?. <i>Journal of Psychiatry and Neuroscience</i> , 2009, 34, 168.	1.4	12
111	A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy. <i>Journal of Psychiatry and Neuroscience</i> , 2009, 34, 433-42.	1.4	19
112	Antipsychotic polypharmacy does not increase the risk for side effects. <i>Schizophrenia Research</i> , 2008, 98, 323-324.	1.1	15
113	Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment. <i>Schizophrenia Research</i> , 2008, 100, 252-260.	1.1	70
114	Risperidone long-acting injection in the treatment of schizophrenia spectrum illnesses: A retrospective chart review of 19 patients in the Vancouver Community Mental Health Organization (Vancouver, Canada). <i>Current Therapeutic Research</i> , 2007, 68, 409-420.	0.5	2
115	Conceptual and Methodological Issues in the Design of Clinical Trials of Antipsychotics for the Treatment of Schizophrenia. <i>CNS Drugs</i> , 2007, 21, 699-714.	2.7	28
116	Determination of Clozapine and its Metabolite, Norclozapine in Various Biological Matrices Using High-Performance Liquid Chromatography. <i>Drug Development and Industrial Pharmacy</i> , 2007, 33, 1158-1166.	0.9	15
117	Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. <i>Journal of Psychiatry and Neuroscience</i> , 2007, 32, 331-8.	1.4	66
118	Corrected QT Intervals in Newly Admitted Geriatric Psychiatric Patients: An Examination of Risk Factors. <i>Canadian Journal of Psychiatry</i> , 2006, 51, 371-376.	0.9	6
119	Clozapine Alone versus Clozapine and Risperidone with Refractory Schizophrenia. <i>New England Journal of Medicine</i> , 2006, 354, 472-482.	13.9	249
120	The Effects of Competitive Displacement on Haloperidol's Plasma Distribution in Normolipidemic and Hyperlipidemic Plasma. <i>Drug Development and Industrial Pharmacy</i> , 2005, 31, 901-905.	0.9	6
121	Competitive Displacement of Clozapine from Plasma Proteins in Normolipidemic and Hyperlipidemic Plasma Samples: Clinical Implications. <i>Drug Development and Industrial Pharmacy</i> , 2005, 31, 331-337.	0.9	8
122	Patterns of Antipsychotic Utilization in a Tertiary Care Psychiatric Institution. <i>Pharmacopsychiatry</i> , 2004, 37, 12-17.	1.7	49
123	Smoking, anticholinergics and schizophrenia. <i>Schizophrenia Research</i> , 2004, 67, 313-314.	1.1	2
124	Clozapine's effects on body weight and resting metabolic rate: a case series. <i>Schizophrenia Research</i> , 2004, 66, 159-162.	1.1	23
125	Prevalence and Outcomes of Pharmaceutical Industry-Sponsored Clinical Trials Involving Clozapine, Risperidone, or Olanzapine. <i>Canadian Journal of Psychiatry</i> , 2004, 49, 601-606.	0.9	47
126	The influence of dyslipidemia on the plasma protein and lipoprotein distribution of haloperidol. <i>European Neuropsychopharmacology</i> , 2003, 13, 33-37.	0.3	8



#	ARTICLE	IF	CITATIONS
127	Generic Clozapine. <i>Pharmacoeconomics</i> , 2003, 21, 1-11.	1.7	12
128	Concomitant clozapine reduces smoking in patients treated with risperidone. <i>European Neuropsychopharmacology</i> , 2002, 12, 77-80.	0.3	38
129	Olanzapine associated weight gain, Hyperglycemia and Neuroleptic Malignant Syndrome: case report. <i>International Journal of Geriatric Psychiatry</i> , 2002, 17, 326-328.	1.3	19
130	Plasma Protein and Lipoprotein Distribution of Clozapine. <i>American Journal of Psychiatry</i> , 2001, 158, 949-951.	4.0	30
131	Antipsychotic Polypharmacy: A Survey of Discharge Prescriptions from a Tertiary Care Psychiatric Institution. <i>Canadian Journal of Psychiatry</i> , 2001, 46, 334-339.	0.9	111
132	Pharmacoeconomics of Clozapine, Risperidone and Olanzapine. <i>CNS Drugs</i> , 2000, 13, 47-76.	2.7	12
133	Theoretical Basis for Loxapine Augmentation in Risperidone Partial Responders. <i>Clinical Drug Investigation</i> , 2000, 19, 257-266.	1.1	3
134	Valproic acid for seizure prophylaxis during clozapine therapy: Where's the evidence?. <i>International Journal of Psychiatry in Clinical Practice</i> , 1999, 3, 249-251.	1.2	5
135	DR. Procyshyn replies. <i>Clinical Therapeutics</i> , 1999, 21, 925-930.	1.1	0
136	Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine. <i>Clinical Therapeutics</i> , 1998, 20, 1203-1217.	1.1	46
137	Engineering Magnesium Selectivity in the Helixâ€œLoopâ€œHelix Calcium-Binding Motif. <i>Archives of Biochemistry and Biophysics</i> , 1995, 323, 115-119.	1.4	23